Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment  

作　　者：Ying Wang[1] Jingyi Zhao[1] Yinhui Yao[1] Junhui Hu[1] Jiuli Hu[1] Xu Xiao[1] Yanwu Zhao[1] 

出　　处：《Pharmacology & Pharmacy》2020年第2期29-37,共9页药理与制药（英文）

摘　　要：Dalbavancin is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to optimize the dosage regimen of dalbavancin in patients with hepatic or renal impairment by Mote Carlo simulation. Pharmacokinetic parameters and microbiological data were collected about dalbavancin. 10,000 patients with renal or hepatic impairment analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more than 90% for dalbavancin in patients with hepatic or renal impairment, except for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in patients with hepatic or renal impairment.Dalbavancin is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to optimize the dosage regimen of dalbavancin in patients with hepatic or renal impairment by Mote Carlo simulation. Pharmacokinetic parameters and microbiological data were collected about dalbavancin. 10,000 patients with renal or hepatic impairment analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more than 90% for dalbavancin in patients with hepatic or renal impairment, except for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in patients with hepatic or renal impairment.

关 键 词：Mote Carlo Simulation DALBAVANCIN HEPATIC IMPAIRMENT RENAL IMPAIRMENT 

分 类 号：R97[医药卫生—药品]